Skip to main content

Precision Oncology Resources: Webinars

Wed
Jun
30
11:00 AM
US Eastern

Sponsored by Stilla

Liquid Biopsy Detection of EGFR Mutations in NSCLC Patients Before and After Osimertinib Therapy

Liquid biopsy is a useful tool for longitudinal monitoring of non-small cell lung cancer (NSCLC) patients, but requires highly sensitive and reliable technologies for accurate detection of genomic alterations.

In this webinar, Evi Lianidou of the University of Athens will discuss a study that evaluated digital PCR (dPCR) for detecting EGFR mutations in plasma cell-free DNA (cfDNA) and corresponding circulating tumor cell (CTC)-derived genomic DNA (gDNA).

The study used Stilla’s Crystal Digital PCR in a group of EGFR-mutant NSCLC patients under osimertinib therapy at two time points: before treatment initiation and at progression of disease.

Dr. Lianidou will share how Crystal Digital PCR allowed her team to track tumor evolution through the detection of low-abundance mutations in cfDNA and CTCs predictive for treatment outcomes of NSCLC patients under osimertinib.

Dr. Lianidou will also discuss other highlights of the study, including:

  • Crystal Digital PCR exhibited high concordance rates in correlation with Roche’s FDA-cleared Cobas technology;
  • In some cases, Crystal Digital PCR was more sensitive than other methods in detecting the T790M mutation, which is the key resistance mutation found during treatment with first-line and second-line EGFR tyrosine kinase inhibitors;
  • The presence of EGFR mutations in paired CTC-derived gDNA revealed discrepancies between CTCs and tumor or cfDNA genotyping.

Sponsored by

Wed
Jun
23
2:00 PM
US Eastern

Sponsored by IONPath

Development of a Predictive Spatial Proteomic Signature for the Progression of Ductal Carcinoma In Situ

Ductal carcinoma in situ (DCIS) is a pre-invasive lesion that is thought to be a precursor to invasive breast cancer (IBC). DCIS comprises approximately 20% of newly diagnosed breast cancer cases, and unlike IBC is not life-threatening. However, if left untreated, up to half of DCIS patients will develop IBC within 10 years, so clinical management has trended towards presuming all patients are progressors and treating them with surgery, radiation therapy, and pharmacological interventions. Thus, understanding the central biological features in DCIS that drive the transition to IBC is a critical unmet need for guiding appropriate patient care.

In this webinar, Dr. Michael Angelo will discuss research his lab conducted to understand how the tumor microenvironment (TME) changes with transition to IBC. Angelo and colleagues used Multiplexed Ion Beam Imaging (MIBI) and a 37-plex antibody staining panel to analyze over 100 clinically annotated surgical resections covering the full spectrum of breast cancer progression. The team compared normal, DCIS, and IBC tissues using machine learning tools for multiplexed cell segmentation, pixel-based clustering, and object morphometrics. They found the transition from DCIS to IBC to progress by coordinated shifts in location and function of myoepithelium, fibroblasts, and infiltrating immune cells in the surrounding stroma. This study offers insight into the etiologies of DCIS and its transition to IBC—emphasizing the importance of the TME stroma—and may serve as a template for how to carry out similar analyses of preinvasive cancers using MIBI spatial proteomic signatures.

Sponsored by

field_file_image_alt_text_value
Fri
Jun
18
12:00 PM
US Eastern

Sponsored by Canexia Health

Disparities in Precision Oncology: Identifying Barriers and Moving Toward Solutions

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019. Although more and more biomarker-informed therapies are being developed and launched on the market, not all patients have access to them due to numerous barriers, among them difficulties accessing genetic testing, limited physician expertise, challenges setting up clinical trials in the community, and reimbursement pressures. Patients' social determinants of health also continue to influence whether they receive, or are even offered, biomarker testing and downstream treatment options. In this panel, experts in the community treating underserved populations and tracking access challenges will discuss the difficulties they are seeing and the solutions they're working on to improve equity in precision oncology.

Sponsored by

Wed
Jun
16
11:00 AM
US Eastern

Sponsored by Biognosys

Precision Oncology in Melanoma Patients Treated with Immunotherapy: Clinical and Technological Perspective

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.

Immune checkpoint inhibitors have proven to be an effective weapon against many solid tumors, but a large proportion of patients do not show a clinical benefit upon treatment. While studies have identified genomic or transcriptomic features responsible to some extent for the lack of response, major advancements in mass spectrometry-based proteomics have only recently enabled comprehensive functional analysis of the final gene products on an unprecedented scale, enabling quantitative and clinically relevant analysis of response mechanisms.

In this webinar, Paolo A. Ascierto, MD of Italy’s National Tumor Institute and Kamil Sklodowski of Biognosys will elaborate on the promise of proteomics for addressing the unmet medical needs of melanoma patients undergoing immunotherapy. 

They will discuss data from a joint project in which cancer tissue samples from late-stage melanoma patients prior to treatment with immune checkpoint inhibitors were analyzed using the Biognosys HRM discovery platform. 

They will share the clinical outcomes as well as the associated proteomic profiles of more than 8,500 identified and quantified proteins, providing a full picture of the capabilities of next-generation proteomics.

About The Series: Next-Generation Proteomics for Precision Oncology

This webinar series will highlight recent advancements in the proteomics field and the impact of proteomics on clinical research in oncology.

Sponsored by

Tue
Jun
08
10:00 AM
US Eastern

Sponsored by Qiagen

Advancing Personalized Oncology with Transcriptomic Profiling and Mechanistic Modeling

Cancer is a complex and heterogeneous disease requiring patient-specific molecular analysis to support treatment decisions. While molecular profiling using DNA-based methods is routine in precision oncology, the incorporation of transcriptomics is not yet well established in the clinic.

In this webinar, Moritz Schütte, head of next-generation sequencing data analysis at Alacris, will explore the advantages of RNA sequencing alone or in combination with whole-exome sequencing as part of a precision oncology workflow.

In addition to discussing how RNA-seq identifies molecular alterations and illuminates the tumor microenvironment, Dr. Schütte will explain how mathematical modeling of molecular data can predict drug sensitivity. Applications will be shown for metastatic melanoma and acute lymphoblastic leukemia.

In this webinar, you will learn:

  • How comprehensive analysis is able to detect actionable targets not accessible by panel analysis;
  • How deep transcriptome profiling gives insights into the tumor microenvironment and immune composition;
  • How transcriptome sequencing can be applied for molecular profiling of acute lymphoblastic leukemias in relapse;
  • How mechanistic modeling offers a highly complementary information layer and enables in silico testing of drug response.

Sponsored by

field_file_image_alt_text_value
Wed
May
26
12:00 PM
US Eastern

Sponsored by Lexogen

CaTCH it if you can! CRISPRa-based Exploration of Therapy Resistant Cell Clones

The emergence of cell clones that are resistant to targeted therapies poses a significant issue in the treatment of metastatic melanoma. While founding clones are often extremely rare in a starting population, their isolation and characterization hold unique potential for understanding disease processes, uncovering novel biomarkers, and developing therapeutic concepts. 

In this webinar, Christian Umkehrer of Vienna’s Research Institute of Molecular Pathology describes the development and application of CaTCH (CRISPRa Tracing of Clones in Heterogeneous Cell Populations), which combines precise mapping of the lineage history of millions of cells with the ability to isolate any given clone alive from a complex population based on genetic barcodes. 

CaTCH enables the retrospective isolation and analysis of founding clones from heterogeneous cell populations prior to evolutionary selection. The approach uses QuantSeq 3’ mRNA-Seq to characterize the isolated clones by efficiently profiling gene expression.

In his presentation Christian Umkehrer will explain how CaTCH can:

  • be used to trace and isolate therapy-resistant clones from complex cancer cell populations in vitro.
  • be applied to in vivo studies by investigating the origins of resistance to clinically relevant RAF/MEK inhibition in an immunocompetent melanoma mouse model.
  • address further fundamental questions in basic and translational research (e.g., how cell identity states and trajectories are determined in therapy resistance, metastasis formation, or somatic cell re-programming).

Sponsored by

Tue
Apr
27
11:00 AM
US Eastern

Sponsored by Biognosys

Oncology in the Time of COVID-19: Quantitative Proteomic Analysis of Anti-IL6 Treated Patients

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Recent advances in mass spectrometry-based proteomics have fostered a more precise, deep, and more functional look into clinical phenotypes. Going beyond traditional genomics, proteomics enables more relevant, quantitative, and informative understanding of diseases and treatments.

Jean-Marie Michot, a medical oncologist at Gustave Roussy Institute and Vito Dozio, Scientific Project Manager at Biognosys, will share a study that illustrates the promise of proteomics in understanding responses to new therapies such as anti-IL-6-based treatment and the impact of comorbidities on clinical outcomes.

They will discuss the results of a joint project in which serum from a cohort of patients infected with COVID-19 was submitted for analysis using the Biognosys HRM discovery proteomics platform. They will share details of proteomic profiles associated with clinical outcome, comorbidities, and the response to anti-IL6 treatment, which provide a comprehensive picture of the potential of using next-generation proteomics to enhance personalized medicine. 

About The Series: Next-Generation Proteomics for Precision Oncology

This webinar series will highlight recent advancements in the proteomics field and the impact of proteomics on clinical research in oncology.

Sponsored by

Thu
Apr
08
11:00 AM
US Eastern

Sponsored by Roche

Interpretation of Comprehensive Genomic Profiling from ctDNA Through Clinical Decision Support

Genomics is central to the precision oncology cascade. After tissue or blood is subjected to next-generation sequencing (NGS) and bioinformatics analysis, the alterations detected must be annotated and interpreted within the context of the individual patient.

This webinar will discuss a single-center prospective interventional study that evaluated the success of a targeted therapy selected by profiling of ctDNA and tissue in patients with advanced and refractory carcinoma.

Samantha Hasenleithner of the Medical University of Graz will discuss the approach, which reflects a true clinical scenario in which both plasma and tissue analytes help inform treatment decisions. Nevertheless, this workflow poses challenges for clinicians in selecting the appropriate treatment.

Clinical decision support may help streamline these variant interpretation and treatment matching workflows, and Dr. Hasenleithner will discuss an evaluation of three such tools and her team’s experience with the Navify Mutation Profiler*.

*For Research Use Only.  Not for use in diagnostic procedures in the US.

Sponsored by

Tue
Mar
30
1:00 PM
US Eastern

Sponsored by Menarini Silicon Biosystems

Circulating Tumor Cells in Breast Cancer: Understanding a Validated Diagnostic Tool for Precision Medicine

This webinar will provide an overview of the current state of circulating tumor cell (CTC) enumeration for clinical use in metastatic breast cancer.

Dr. Massimo Cristofanilli, Associate Director of Translational Research and Precision Medicine at Robert Lurie Cancer Center, Northwestern University, will review the evidence, as well as clinical case studies demonstrating how CTCs can be utilized in clinical practice and clinical research studies in metastatic breast cancer. 

A prominent figure in the liquid biopsy field, Dr. Cristofanilli led a pivotal study demonstrating the prognostic value of CTC enumeration using the semiautomated CellSearch technology. CellSearch has been cleared by the US Food and Drug Administration for detecting and enumerating circulating tumor cells to help manage patients with metastatic breast, prostate, and colorectal cancers.

Dr. Cristofanilli will discuss future developments and applications of CTCs in oncology. The session will wrap up with a live Q&A with Dr. Cristofanilli.

Sponsored by

Thu
Mar
25
1:00 PM
US Eastern

Sponsored by Foundation Medicine

Virtual Molecular Tumor Board Series: What to Do with a ‘Negative’ Molecular Panel Case

In this session, the fourth in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling identified no clear molecular markers to help guide personalized therapy.

The application of comprehensive genomic profiling (CGP) in patients with metastatic solid tumors aims to identify therapeutic options that were not otherwise evident with standard workup. However, CGP -- even when it analyzes patient samples against 500+ potential mutations — does not always identify an actionable target.  In these cases, clinicians still need to develop a care plan based on best evidence and individual patient goals.

Our panel will discuss several of these cases in detail and recommend next steps.

The session will wrap up with a live Q&A in which attendees can discuss the cases with the Virtual Molecular Tumor Board panelists.

About The Series

The Virtual Molecular Tumor Board Series is an interactive and educational online program intended to highlight the key role that molecular tumor boards play in implementing precision oncology.

The series will underscore the collaborative nature of genomic medicine by assembling a multidisciplinary panel of experts who will meet virtually for four one-hour sessions. In each session, the panel will review the genomic and clinical evidence for anonymized patients who have had their tumors sequenced as part of clinical management. The panel will discuss each case and recommend a course of treatment.

Precision Oncology News would like to thank Clariifi for assistance in planning and executing this educational webinar series.


Sponsored by

field_file_image_alt_text_value
Tue
Mar
23
12:00 PM
US Eastern

Sponsored by Roche

ctDNA MRD Detection and Personalized Oncogenomic Analysis in Colorectal Cancer

This webinar will discuss findings from the study, in which molecular residual disease (MRD) was assessed using circulating tumor DNA (ctDNA) without prior mutational knowledge in oligometastatic colorectal cancer (CRC) patients who had received neoadjuvant chemotherapy. This study also investigated urine as an alternative analyte for ctDNA MRD detection.

Dr. Aadel Chaudhuri of Washington University will share details of the study, which applied Avenio targeted next-generation sequencing (NGS) *to plasma, tumor and urine samples acquired on the day of curative-intent surgery from prospectively enrolled oligometastatic CRC patients.

The study demonstrated that tumor-naïve plasma ctDNA analysis can sensitively and specifically detect MRD in patients with oligometastatic CRC after neoadjuvant chemotherapy, while urine-based ctDNA MRD detection is less sensitive than plasma. Dr. Chaudhuri will discuss these findings in detail.

* For Research Use Only.  Not for use in diagnostic procedures.

Sponsored by

Thu
Mar
11
1:00 PM
US Eastern

Sponsored by Foundation Medicine

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Precision medicine has been focused on the presence of activating mutations or gene amplifications. However, recent data has shown that the presence of gene fusions also offer a unique treatment opportunity, with the potential for durable clinical responses.

Our panel will discuss several such clinical cases in detail and recommend a course of treatment based on the genomic profiles of the patients.

The session will wrap up with a live Q&A in which attendees can discuss the cases with the Virtual Molecular Tumor Board panelists.

About The Series

The Virtual Molecular Tumor Board Series is an interactive and educational online program intended to highlight the key role that molecular tumor boards play in implementing precision oncology.

The series will underscore the collaborative nature of genomic medicine by assembling a multidisciplinary panel of experts who will meet virtually for four one-hour sessions. In each session, the panel will review the genomic and clinical evidence for anonymized patients who have had their tumors sequenced as part of clinical management. The panel will discuss each case and recommend a course of treatment.

Precision Oncology News would like to thank Clariifi for assistance in planning and executing this educational webinar series.

Sponsored by

field_file_image_alt_text_value
Thu
Feb
25
1:00 PM
US Eastern

Sponsored by Foundation Medicine

Virtual Molecular Tumor Board Series: Common Driver Mutations in ‘Off-Label’ Tumor Types

In this session, the second in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review cases in which patient genomic profiles exhibit common driver mutations in tumor types considered “off label” for targeted therapies associated with those mutations.

US Food and Drug Administration approvals for targeted anticancer therapy are most often for specific types of cancer that possess specific driver mutations. However, the broad application of comprehensive genomic profiling has identified the presence of potential “druggable” driver mutations in malignancies for which FDA approval is not yet obtained.

Our panel will discuss several such clinical cases in detail and recommend a course of treatment based on the genomic profiles of the patients.

The session will wrap up with a live Q&A in which attendees can discuss the cases with the Virtual Molecular Tumor Board panelists.

About The Series 

The Virtual Molecular Tumor Board Series is an interactive and educational online program intended to highlight the key role that molecular tumor boards play in implementing precision oncology.

The series will underscore the collaborative nature of genomic medicine by assembling a multidisciplinary panel of experts who will meet virtually for four one-hour sessions. In each session, the panel will review the genomic and clinical evidence for anonymized patients who have had their tumors sequenced as part of clinical management. The panel will discuss each case and recommend a course of treatment.

Precision Oncology News would like to thank Clariifi for assistance in planning and executing this educational webinar series.


Sponsored by

field_file_image_alt_text_value
Thu
Feb
11
1:00 PM
US Eastern

Sponsored by Foundation Medicine

Virtual Molecular Tumor Board Series: HRD and DNA Damage Repair

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Initial interest in homologous recombination genes was focused on pathologic mutations associated with risk of inherited breast, prostate, pancreatic, and/or gynecological malignancies. HRD has recently emerged as a biomarker to predict sensitivity to PARP inhibitors, and the identification of these alterations has become important, accordingly.

Our panel will discuss several such clinical cases in detail and recommend a course of treatment based on the genomic profiles of the patients.

The session will wrap up with a live Q&A in which attendees can discuss the cases with the Virtual Molecular Tumor Board panelists.

About The Series 

The Virtual Molecular Tumor Board Series is an interactive and educational online program intended to highlight the key role that molecular tumor boards play in implementing precision oncology.

The series will underscore the collaborative nature of genomic medicine by assembling a multidisciplinary panel of experts who will meet virtually for four one-hour sessions. In each session, the panel will review the genomic and clinical evidence for anonymized patients who have had their tumors sequenced as part of clinical management. The panel will discuss each case and recommend a course of treatment.

Precision Oncology News would like to thank Clariifi for assistance in planning and executing this educational webinar series.



Sponsored by

field_file_image_alt_text_value
Wed
Dec
02
12:30 PM
US Eastern

Sponsored by Qiagen

PIK3CA Mutations in Advanced Breast Cancer: The Vital Role of Tissue and Plasma Companion Diagnostics

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.

In this webinar, Dr. Lawrence Weiss from NeoGenomics will discuss his experience with the validation and implementation of testing for actionable PIK3CA mutations using the therascreen PIK3CA RGQ PCR Kit.

The webinar will provide an overview of an innovative approach to detecting PIK3CA mutations by testing either tissue or plasma samples and the benefits this brings to breast cancer care. An FDA-approved companion diagnostic test, the therascreen PIK3CA RGQ PCR Kit helps clinicians identify actionable PIK3CA mutations in breast cancer cases to inform patient treatment choices.

The webinar will focus on the following topics:

  • Overview of HR+/HER2- breast cancer progression and resistance to endocrine therapy.
  • The biology and activation of the PI3K pathway and its role in cancer.
  • Validation and implementation of the therascreen PIK3CA RGQ PCR Kit for testing of both formalin-fixed, paraffin-embedded tissue and plasma samples.
  • The provision of Day 1 availability of PIK3CA mutation companion diagnostic testing.

The therascreen PIK3CA RGQ PCR Kit is intended for in vitro diagnostic use. Products and product claims may differ from country to country based on regulations and approvals. Contact your country representative for further details.

Sponsored by

field_file_image_alt_text_value